Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2017-09-18 Regulatory Filings
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 1% confidence The document is a press release dated September 18, 2017, announcing the 'Total number of outstanding shares as well as its voting rights as of August 31, 2017.' It explicitly cites French regulatory articles (L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter) which mandate the disclosure of share capital and voting rights figures. This type of mandatory disclosure regarding the total number of shares and voting rights is typically classified as a Major Shareholding Notification (MRQ) or, more broadly, a Regulatory Filing (RNS) if no other specific category fits. Since the core content is a formal declaration of the total share count and voting rights, which is a key component of major shareholding/capital structure reporting, MRQ is the most specific fit among the options, although it is not strictly a change in a *shareholder's* holding, but rather the total base figure. However, given the options, this relates directly to capital structure reporting required by market authorities. If the document were announcing a change in a specific shareholder's stake crossing a threshold, MRQ would be perfect. Since it's the total base figure, it's a fundamental regulatory disclosure. Comparing the options, 'Major Shareholding Notification' (MRQ) often encompasses these base figures as they are required for threshold calculations. If MRQ is too specific for the total base, 'Regulatory Filings' (RNS) is the fallback. Given the context of mandatory disclosure of share counts under AMF rules, MRQ is a strong candidate as it deals with the mechanics of share ownership reporting. Let's re-evaluate: This is a routine, periodic disclosure of the total share count, not necessarily a notification triggered by a shareholder crossing a threshold (which is the typical trigger for MRQ). Therefore, it fits best under the general regulatory announcement category, RNS, as it is a mandatory filing that doesn't fit the specific definitions of DIV, CAP, SHA, or DIRS.
2017-09-18 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is a press release ("COMMUNIQUE DE PRESSE") published on September 18, 2017, by ADOCIA SA. The core content explicitly states that the company is publishing the number of shares composing its capital and the corresponding voting rights as of August 31, 2017, in compliance with French commercial code and AMF regulations (Article L.233-8 II and Article 223-16). This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to major shareholding notifications or general capital structure updates. Since the document provides the actual figures (Number of shares, Gross Voting Rights, Net Voting Rights) and is a formal announcement of this specific data point, it aligns best with 'Major Shareholding Notification' (MRQ) or a general regulatory disclosure. Given the specific nature of reporting total voting rights, MRQ is the most precise fit among the options, as changes in total voting rights often trigger these reports, even if no single shareholder crossed a threshold. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a direct regulatory data disclosure.
2017-09-18 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that data supporting two of the company's programs have been selected for presentation at the "53rd Annual Meeting of the European Association for the Study of Diabetes (EASD)". This is an announcement about participation in a scientific/medical conference, not the release of a formal regulatory filing (like 10-K or IR) or a general regulatory notice (RNS). The content focuses on scientific data presentation schedules and abstracts, which aligns best with materials presented or discussed at an Annual General Meeting (AGM) or a similar large industry meeting where presentations occur. Since the document is an announcement about presentations at a major industry meeting (EASD Annual Meeting), and not a formal shareholder AGM, the closest fit among the provided codes that relates to presentations and meeting materials is AGM-R, although it is an industry meeting, not a shareholder meeting. However, given the options, this is a presentation announcement related to scientific findings, which is often grouped with investor/meeting materials. If the document were about the company's own shareholder AGM, AGM-R would be perfect. Since it is an announcement about presenting data at a major external medical meeting, and it is not an Earnings Release (ER), Investor Presentation (IP), or a general Regulatory Filing (RNS), AGM-R is the most contextually relevant choice for a meeting-related announcement, even if the meeting is external. FY 2017
2017-09-05 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that data related to Adocia's products (BioChaperone® Lispro and BioChaperone® Glargine GLP-1) have been selected for presentation at the 53rd annual congress of the European Association for the Study of Diabetes (EASD). It details the content of the presentations (posters) and includes standard company boilerplate and contact information. This is not a full financial report (10-K or IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. It is an announcement about scientific data being presented at a medical conference. This type of announcement, which is a general corporate update regarding scientific progress and conference participation, fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate communication, although it is primarily scientific news. Given the options, RNS is the most appropriate fallback for a press release announcing scientific presentation details that doesn't fit a more specific category like ER or CT.
2017-09-05 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific corporate event: the hiring of a new Medical Director (Dr. Stanislav Glezer). This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). The document is a formal announcement about personnel change.
2017-07-26 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the appointment of a new Chief Medical Officer, Dr. Stanislav Glezer. This type of announcement concerns changes in senior management personnel. Reviewing the definitions, the category 'Board/Management Information (Code: MANG)' covers 'Announcement of changes in the company's board of directors or senior management.' This is a direct match. It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it pertains to a specific internal management change.
2017-07-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.